Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson’s Disease and Related Dementia

Table 5

Univariate linear regression analysis of anti-Parkinson’s disease drugs for serum butyrylcholinesterase activity in PD patient.

Variable	Patient percentage	Beta value	value
Total patients	76 (100%)	/	/
Levodopa and Benserazide Hydrochloride Tablet	54 (71.1%)	−0.169	0.143
Carbidopa and Levodopa-CR Tablet	8 (10.5%)	−0.106	0.362
Levodopa Tablet	1 (1.3%)	0.042	0.717
Piribedil-SR Tablet	27 (35.5%)	0.759	0.450
Pramipexole Dihydrochloride Tablet	15 (19.7%)	−0.042	0.720

PD, Parkinson’s disease; Beta value, adjusted regression coefficient; CR, controlled release; SR, sustained release.